| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10920367 | Radiotherapy and Oncology | 2005 | 9 Pages |
Abstract
As expected from radiobiological considerations, HFX reduces GI and GU late toxicities. Concerning early bRFS, our clinical findings suggest that HFX is no less effective than STD when delivering an isoeffective (α/β=10) dose. Despite the relatively short follow-up, this result appears to be inconsistent with a low α/β ratio for prostate cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Riccardo Valdagni, Corrado Italia, Paolo Montanaro, Angelo Lanceni, Paola Lattuada, Tiziana Magnani, Claudio Fiorino, Alan Nahum,